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RetrotransposonHuman cytidine deaminases, including APOBEC3G (A3G) and A3F, are part of a cellular defense system
against retroviruses and retroelements including non-LTR retrotransposons LINE-1 (L1) and Alu. Expression
of cellular A3 proteins is sufﬁcient for inhibition of L1 and Alu retrotransposition, but the effect of A3 proteins
transferred in exosomes on retroelement mobilization is unknown. Here, we demonstrate for the ﬁrst time
that exosomes secreted by CD4+H9 T cells and mature monocyte-derived dendritic cells encapsidate A3G
and A3F and inhibit L1 and Alu retrotransposition. A3G is the major contributor to the inhibitory activity of
exosomes, however, the contribution of A3F in H9 exosomes cannot be excluded. Additionally, we show that
exosomes encapsidate mRNAs coding for A3 proteins. A3G mRNA, and less so A3F, was enriched in exosomes
secreted by H9 cells. Exosomal A3G mRNA was functional in vitro. Whether exosomes inhibit retro-
transposons in vivo requires further investigation.ll rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
Long interspersed elements (L1) are the only active autonomous
non-LTR retrotransposons in the human genome. While L1s make up
about 17% of the human genome, only 80 to 100 of the over 500,000
copies can retrotranspose (Kazazian, 2004). L1s are about 6 kb long,
harbor an internal polymerase II promoter and encode two open
reading frames (ORFs): ORF1p coding for a 40 kDa protein with RNA
binding and RNA chaperone activity (Holmes et al., 1992; Kolosha and
Martin, 2003; Martin et al., 2000), and ORF2p coding for a 150 kDa
protein with endonuclease (Feng et al., 1996), reverse transcriptase
(Mathias et al., 1991), and C-terminal cysteine-rich domains (Fanning
and Singer, 1987). Upon translation, L1 RNA assembles with ORF1p
and ORF2p and the formed ribonucleoprotein complex moves to the
nucleus, where an endonuclease makes a single-stranded nick. The
reverse transcriptase uses the nicked DNA to prime reverse
transcription of the L1 RNA, leading ultimately to integration of L1
cDNA (Babushok and Kazazian, 2007). In contrast to L1, Alu elements
are non-autonomous and are mobilized by the L1 retrotransposition
machinery (Dewannieux et al., 2003; Ostertag and Kazazian, 2001). As
insertions of both Alu and L1 elements into the human genome may
cause a number of human genetic disorders (Callinan and Batzer,
2006;Wallace et al., 2008), under normal conditions retrotransposons
are silenced. Mechanisms protecting cells against retrotranspositioninclude repression of transcription by DNA methylation (Roman-
Gomez et al., 2005), premature polyadenylation (Perepelitsa-Belancio
and Deininger, 2003), aberrant splicing (Belancio et al., 2006) or RNA
interference (Yang and Kazazian, 2006). Another strategy is editing of
nucleic acids by the APOBEC3 (A3) family of cellular cytidine
deaminases.
Themost prominentmember of this family, APOBEC3G (A3G), ﬁrst
identiﬁed through its ability to inhibit replication of vif-deﬁcient HIV-
1 (Sheehy et al., 2002), also functions as a post-entry restriction factor
against wild-type viruses (Chiu et al., 2005; Khatua et al., 2009; Pion et
al., 2006; Vetter and D'Aquila, 2009; Wang et al., 2008a). Although
deaminase-independent activities of A3G are postulated to contribute
to its antiviral function (Bishop et al., 2006; Holmes et al., 2007;
Newman et al., 2005), there is strong evidence that HIV-1 restriction
requires A3G deaminase activity when the protein is not over-
expressed (Browne et al., 2009; Miyagi et al., 2007; Schumacher et al.,
2008). In mammals, A3G also restricts replication of a variety of
endogenous retroviruses (Esnault et al., 2005; Esnault et al., 2006,
2008; Schumacher et al., 2008) and retroelements including Alu
(Bogerd et al., 2006b; Chiu et al., 2006; Hulme et al., 2007) and L1
(Bogerd et al., 2006b; Chen et al., 2006; Kinomoto et al., 2007;
Muckenfuss et al., 2006; Niewiadomska et al., 2007; Schumann, 2007;
Stenglein and Harris, 2006; Tan et al., 2009; Turelli et al., 2004). The
expansion of a single A3 gene in mice to the seven A3 genes found in
primates correlates with the signiﬁcant enhancement of restriction of
endogenous retroelements seen in primates. This supports the
suggestion that A3 proteins provide a cellular defense mechanism
against endogenous and exogenous invaders (Esnault et al., 2005).
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exosomes is secreted by CD4+H9 T cells (Khatua et al., 2009). This
was corroborated by the observation that a fraction of cellular A3G
associates with multivesicular bodies (MVB)/late endosomes (Alce
and Popik, 2004), organelles that release intralumenal vesicles as
exosomes after fusion with the plasma membrane (de Gassart et al.,
2004; Stoorvogel et al., 2002; Thery et al., 2002). This observation
suggests that A3G and possibly other A3 proteins are transmitted
between cells, in exosomes, and contribute to an antiretroviral
defense mechanism (Khatua et al., 2009).
The biological role of exosomes is not fully understood. Secretion
of transcription factors (Ratajczak et al., 2006a, 2006b), morphogenic
proteins (Liegeois et al., 2006) as well as cellular mRNAs and miRNAs
(Bruno et al., 2009; Deregibus et al., 2007; Valadi et al., 2007) in
association with exosomes suggests that these vesicles may epige-
netically reprogram the recipient cells and may play a role during
embryogenesis. Although retrotransposition occurs sporadically in
somatic cells, L1 and Alu transpositions are most active in germ cells
and during early embryogenesis (Garcia-Perez et al., 2007; Prak et al.,
2003; van den Hurk et al., 2007). We speculate that secretion ofFig. 1. Effect of A3 proteins and exosomes on L1 retrotransposition. 293T cells were transfecte
tagged A3 expression plasmids. Cells transfected with pL1RP-EGFP only were exposed to exos
(Blood exo). (A) After 5 days, cells were observed by ﬂuorescence microscopy and (B) tryps
retrotransposition level in cells transfected with pL1RP-EGFP (in the absence of A3 proteins
EGFP. Error bars, mean values±SDs of triplicate samples. Similar results were obtained in 4 in
or in exosomes (right panel) was analyzed by SDS-PAGE followed by immunoblotting withexosomes including A3G or other A3 proteins, in combination with
functional mRNAs coding for these proteins, provides an additional
line of defense against retroelements, especially in recipient cells that
do not express or express only suboptimal levels of these proteins.
In the present study, we tested whether exosomes secreted by cells
expressing A3G can restrict retrotransposition in recipient cells. We
demonstrate that exosomes secreted by cells expressing A3G and A3F
potently restrict L1 andAlu retrotransposition. This leads us to speculate
that exosomes contribute to anti-retroelement defenses in vivo.
Results
Exosomes secreted by H9 CD4+ T cells and mature monocyte-derived
dendritic cells (M-DCs) inhibit L1 retrotransposition
Previous reports have shown that multiple human A3 proteins
inhibit retrotransposition of L1 to different degrees, with A3A, A3B,
A3C and A3F being the most effective and A3DE, A3G, and A3H having
a smaller or negligible effect on L1 mobilization (Bogerd et al., 2006b;
Chen et al., 2006; Kinomoto et al., 2007; Muckenfuss et al., 2006;d with a pL1RP tagged with an EGFP retrotransposition indicator cassette and HA- or V5-
omes (20 μg/ml) secreted by H9, SupT1, M-DC, or isolated from peripheral blood plasma
inized, ﬁxed with 3% paraformaldehyde and subjected to ﬂow cytometry analysis. The
or exosome treatment) was set as 100%. EF05J=negative control with inactive pL1RP-
dependent experiments. (C) Expression of A3G proteins in transfected cells (left panel)
anti-HA or anti-V5. A3G in exosomes was detected with anti-A3G antibodies.
Fig. 2. Expression of A3G and A3F in exosomes. Exosomes were puriﬁed from cell
culture supernatants or from blood plasma of 2 different healthy blood donors. Cell and
exosome lysates (20 and 10 μg/lane, respectively) were separated by SDS-PAGE and
analyzed byWestern blotting for the presence of A3G, A3F, and exosome markers Rab7
and Alix. In addition to the 70–75 kDa form of Alix detected predominantly in cells,
higher molecular forms of Alix (95–105 kDa)were detected, particularly in exosomes. A
slower migrating form of A3G was speciﬁcally detected in H9 exosomes. Note that A3F
was detected in exosomes puriﬁed from blood plasma of donor 2 but not donor 1.
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2004). We previously showed that A3G is speciﬁcally packaged and
secreted by cells in association with exosomes that confer resistance
to HIV-1 after internalization by recipient cells (Khatua et al., 2009).
To determine whether exosomes secreted by cells expressing A3G or
other A3 proteins show inhibitory activity against retroelements, we
analyzed the effect of isolated exosomes on L1 retrotransposition
using an established 293T cell culture-based retrotransposition
reporter assay (Brouha et al., 2003; Ostertag et al., 2000; Wei et al.,
2000).
For this assay, we used a construct in which an active L1RP (L1)
element (Kimberland et al., 1999; Ostertag et al., 2000) was tagged
with a retrotransposition indicator EGFP cassette. The EGFP gene,
under control of a CMV promoter, was interrupted by a γ-globin
intron and was cloned in a transcriptional orientation opposite to L1.
EGFP was expressed only after the full-length L1 was transcribed, the
intron was removed by cellular splicing machinery, and the RNA was
reverse transcribed and integrated into the host genome. 293T cells
were transfected with the L1 reporter construct alone or in
combination with plasmids expressing various human A3 proteins
(Fig. 1). In addition, cells transfected with L1 were exposed to
exosomes secreted by H9 CD4+ T cells, activated M-DC, and SupT1
CD4+ T cells, or exosomes isolated from the blood plasma of normal
blood donors. 293T cells were also transfected with EF05J, a negative
control derived from L1RP containing disabling mutations in ORF1
(Farkash et al., 2006).
Retrotransposition events were monitored by the appearance of
EGFP-positive cells 5–7 days after transfection (Fig. 1A) and
quantitated by ﬂow cytometry (Fig. 1B). Expression of A3 proteins,
used as controls, showed an anticipated inhibition of L1 retro-
transposition, with cells containing A3A, A3B, and A3F having the
most potent inhibitory activity. Retrotransposition events were also
inhibited by A3C (about 43%) and by A3G (about 30%). A3H showed
no activity against L1 under the conditions of assay. Observed
differences in L1 inhibition were most likely A3 dependent since all
A3 proteins were expressed in 293T cells at roughly comparable levels
(Fig. 1C). Similarly, exosomes isolated from various cellular sources
had different anti-L1 activities. While the effect of transient
expression of A3G on L1 was only moderate (30% decrease) (Fig.
1B), H9 and M-DC exosomes with A3G inhibited L1 retrotransposition
(in contrast to A3G-negative exosomes secreted by SupT1 cells or
derived from blood plasma). In particular, exosomes secreted by A3G-
positive H9 cells inhibited L1 transposition by about 75%, while
exosomes released from mature M-DCs inhibited L1 transposition by
about 50%. Together, these results suggest that in addition to A3G,
other A3 proteins present in exosomes contribute to L1 inhibition.
Since A3F expressed in 293T cells was more potent in inhibiting L1
than A3G (Fig. 1B), we determined if A3F was detectable in H9-,
SupT1-, mature M-DC-, and plasma-derived exosomes, and thus
might contribute to the capacity of these exosomes to inhibit L1
retrotransposition. As shown by Western blot analysis (Fig. 2), A3G
was not only expressed by H9 T cells and mature M-DC, but also
detected in exosomes secreted by these cells. Two forms of A3G were
detected in H9 exosomes, while only faster migrating A3G was
present in H9 cells (Khatua et al., 2009). In addition to H9 cells andM-
DC, A3F was also detectable in both SupT1 cells and exosomes, as well
as in blood exosomes derived from one of the two blood donors.
However, unlike H9 exosomes that appeared to concentrate A3F
about 3-fold in comparison to H9 cells, the expression of A3F in
exosomes secreted by M-DC and SupT1 cells was lower than in their
respective cell samples. Comparable levels of Rab7 expression in cells
and exosomes suggest that observed differences in A3G and A3F were
not caused by unequal protein loading on a gel. Different forms of Alix,
a typical exosomal marker, were also detected in exosomes and in
cells, with slower migrating forms of Alix detected predominantly in
exosomes (Khatua et al., 2009). Together, H9 exosomes expressedabout 10 times more A3F protein than SupT1 or M-DC exosomes.
Thus, the presence of both A3G and A3F in exosomes may translate
into the higher potency of H9 exosomes against L1 mobilization.
H9 cells secrete exosomes enriched in A3G and A3F mRNAs
In addition to hundreds of proteins, exosomes encapsidate
numerous cellular mRNAs that can be delivered and translated into
corresponding proteins and in turn profoundly affect gene expression
in target cells (Deregibus et al., 2007; Ratajczak et al., 2006a; Skog et
al., 2008; Valadi et al., 2007). To investigate the possibility that H9
exosomes incorporate mRNAs coding for A3 proteins, total RNA was
isolated from H9 and SupT1 cells and exosomes and analyzed for the
presence of A3 speciﬁc mRNAs using real-time RT-PCR. Expression of
A3 mRNAs was normalized against GAPDH mRNA. Since the
expression of A3C mRNA was the highest among tested A3 mRNAs
in H9 cells and exosomes, it was set as 1 (100%) and the levels of other
A3 mRNAs were expressed relative to the level of A3C mRNA. H9 cells
expressed A3G and A3F mRNAs at a level of about 48% and 27%,
respectively, of A3CmRNA (Fig. 3A). In contrast, SupT1 cells expressed
signiﬁcantly lower levels of A3 mRNAs with the highest levels of A3C,
A3DE and A3F mRNAs ranging between 7% and 10% of H9 A3C mRNA
level. In SupT1 exosomes, A3 mRNAs were almost undetectable with
the exception of A3FmRNA (Fig. 3B). The very low levels of A3mRNAs
in SupT1 exosomes is in keeping with the low expression of these
proteins in these cells. H9 exosomes, on the other hand, were
enriched in A3G and A3F mRNAs in addition to A3C mRNA, with A3F
mRNA expressed at 38% and A3G expressed at 97% of A3C mRNA level
in H9 exosomes. To investigate whether exosomal A3G mRNA is
functional, we performed an in vitro translation assay using polyA+
mRNA isolated directly from H9 exosomes (Fig. 3C). Using rabbit anti-
A3G antibodies, we detected a protein product around 43 kDa that
corresponds to A3G. Low intensity bands at around 37 kDa and
stronger bands around 20 kDa were detected in all in vitro reactions
even in the absence of added mRNA, suggesting that they represent
non-speciﬁc proteins. In conclusion, H9 exosomes encapsidate several
A3 mRNAs and some of them can be translated in vitro into proteins.
In contrast, exosomes secreted by SupT1 cells were generally depleted
of A3 mRNAs.
A3G is a major determinant of restriction of Alu retrotransposition
by exosomes
Recent studies have shown that A3G strongly restricts Alu
retrotransposition, possibly by sequestering Alu RNAs in cytoplasmic
Fig. 3. Expression of A3 mRNAs in CD4+T cells and exosomes. Total RNA was extracted
from H9 and SupT1 cells and from exosomes secreted by these cells and subjected to
real-time RT-PCR. Levels of A3mRNAs in cells (A) and in exosomes (B) were normalized
against GAPDHmRNA levels and were expressed relative to A3CmRNA levels that were
set as 1.0 in both H9 cells and H9 exosomes. Error bars, mean values±SD of triplicate
samples. (C) A3G mRNA present in H9 exosomes is functional. PolyA+mRNA (1 μg)
isolated from H9 exosomes (exo) was subjected to an in vitro translation using a human
in vitro protein expression assay. Samples without RNA (Ø, negative control) or
containing GFP mRNA (positive control) were included. Translation reaction products
were separated by SDS-PAGE and analyzed byWestern blotting for the presence of A3G
and GFP. Molecular weight markers (in kDa) are shown. NS, non-speciﬁc protein.
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preventing access of Alu RNAs to the nuclear L1 machinery (Bogerd
et al., 2006b; Chiu et al., 2006; Gallois-Montbrun et al., 2008; Hulme et
al., 2007). To examine the ability of exosomes to inhibit retro-
transposition of Alu in human cells, we performed an L1-dependent
Alu retrotransposition assay using the neoTet marked Alu reporter
construct as described (Dewannieux et al., 2003). HeLa cells were
cotransfected with an Alu reporter and L1 expression vector p220.
CMV-L1 (Esnault et al., 2006) and treated for 48 h with exosomes of
different cell origins. The appearance of neomycin-resistant colonies
provided a direct measure of successful Alu retrotransposition. Thecolonies were stainedwith crystal violet and counted twoweeks later.
To ensure measurement of L1-dependent Alu transposition, we
included negative controls by transfecting HeLa cells with Alu and a
GFP expression vector or transfecting the cells only with either the
neoTet marked Alu reporter or with L1 vector. No retrotransposition
events were detected in negative controls (Fig. 4).
Consistent with previous observations (Bogerd et al., 2006b; Chiu
et al., 2006; Hulme et al., 2007), expression of A3G from transfected
vector inhibited over 98% of Alu retrotransposition events. H9
exosomes were almost equally potent and inhibited on average 92–
96% of Alu retrotranspositions. To investigate the contribution of A3G
to the observed Alu inhibition by H9 exosomes, we ﬁrst tried down-
regulating the expression of A3G in H9 cells by using short interfering
RNA. However this approach did not substantially reduce A3G protein
expression in either H9 cells or in exosomes (Khatua et al., 2009), and
thus did not appreciably reduce the inhibitory effect previously seen
on Alu transposition (not shown).
To overcome this problem, we transfected A3G-negative SupT1
cells with GFP-A3G or GFP expression vectors and collected exosomes
to be used in retrotransposition assays. Exosomes secreted by SupT1
cells transfected with GFP-A3G (SupT1/A3G exo) inhibited Alu
retrotransposition by 68%, while exosomes derived from GFP-
transfected cells (not shown) or parental A3G-negative SupT1 cells
inhibit Alu retrotransposition only marginally (Fig. 4). Similarly,
exosomes isolated from peripheral blood plasma samples of 2
different healthy donors showed no inhibitory effect on Alu retro-
transposition. In contrast, exosomes secreted by mature M-DC that
expressed A3G (Fig. 1C) inhibited Alu transposition by 55%. Since
exosomes isolated from blood plasma (Fig. 1C) and secreted by SupT1
(Fig. 2) did not express detectable levels of A3G, these results suggest
that the inhibitory effect of exosomes against Alu retrotransposition
are affected, at least in part, by the presence of encapsidated A3G.
Discussion
Retrotransposons constitute about 45% of the human genome. To
protect genome stability, eukaryotic cells have developed several
strategies to restrict proliferation of transposable elements. One of the
strategies adopted by cells is silencing the mobilization of retro-
elements by cytidine deaminases belonging to the family of A3
proteins. Human A3 proteins show some preferences with regard to
the inhibition of non-LTR transposons, L1 or Alu. For instance, A3A and
A3B inhibit both L1 and Alu retrotransposition, A3C and A3F mostly
inhibit L1 (Bogerd et al., 2006b; Chen et al., 2006; Muckenfuss et al.,
2006; Stenglein and Harris, 2006), while A3G preferentially inhibits
Alu mobilization, with a marginal effect on L1 (Bogerd et al., 2006b;
Chiu et al., 2006; Hulme et al., 2007). However, a stronger A3G
mediated inhibitory activity on L1 retrotransposition has also been
reported (Kinomoto et al., 2007; Niewiadomska et al., 2007). Recently,
an inhibitory activity against Alu retrotransposition has been
attributed to A3H and A3DE (Tan et al., 2009) as well as A3F
(Gallois-Montbrun et al., 2008). Since cells may express suboptimal
levels or different forms of A3 proteins, it is likely that the supply of
speciﬁc A3 proteins in exosomes may inﬂuence the extent and
speciﬁcity of anti-retroelement activity in the recipient cell. Indeed,
we have shown that A3G transmitted in exosomes and functionally
expressed in HIV-1 susceptible cells strongly inhibits replication of
HIV-1 in exosome-receiving cells (Khatua et al., 2009).
Exosomes are small membrane vesicles released by various types
of cells, and carry molecular imprints of cells from which they were
secreted. Exosomes originate from intralumenal vesicles of multi-
vesicular bodies (MVBs) that form during the inward budding of
limiting membranes of endosomes. Fusion of MVBs with the plasma
membrane releases exosomes into intercellular space where they are
believed to play a role in intercellular communication by transferring
biologically active molecules to recipient cells. Detection of mRNA and
Fig. 4. Effect of exosomes on L1-mediated Alu retrotransposition. HeLa cells were cotransfected with an Alu construct tagged with the neoTet retrotransposition indicator cassette and
an L1 construct (Alu+ L1), with or without an A3G expression vector. Cells transfected with Alu+ L1 were exposed with different exosomes (20 μg/ml). Three days post-
transfection, cells were subjected to selection in G418 for 14 days and resistant colonies were ﬁxed, stained with crystal violet (A) and counted (B). As negative controls, cells were
mock transfected (cells only) or transfected with L1 alone, Alu neoTet alone (Alu) or together with irrelevant GFP gene (Alu+ GFP). Retrotransposition efﬁciency was expressed
relative to the positive control (Alu+ L1), which was set as 100%. Values represent the means±SD of triplicate samples. Similar results were obtained in 4 independent experiments.
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also involved in exchange of genetic information between cells
(Valadi et al., 2007).
In this study, we tested the hypothesis that exosomes secreted by
cells expressing A3G and A3F restrict mobilization of L1 and Alu
retroelements in target cells. Using an in vitro assay to quantify the
frequency of L1 and Alu retrotransposition, we have conﬁrmed that
transiently overexpressed A3 proteins inhibit these non-LTR retro-
elements to different extents, with A3A, A3B and A3F restricting L1,
and A3G strongly inhibiting Alu retrotransposition. Somewhat
surprisingly, H9 exosomes that were originally found to encapsidate
A3G and inhibited HIV-1 replication (Khatua et al., 2009) had a strong
inhibitory activity against L1. Since A3G only weekly reduced L1
activity in our assays, this suggests that H9 exosomes encapsidate
other A3 protein(s) that are able to inhibit L1. Indeed, we have
identiﬁed A3F in H9 exosomes suggesting that this cytidine
deaminase, alone or in combination with A3G or other restriction
factors, is responsible for the observed inhibitory effect on L1
retrotransposition (Muckenfuss et al., 2006). Therefore, the moderate
activity of exosomes secreted by mature M-DC may be explained by
the lower levels of A3F detected in these exosomes. However, it is
possible that other A3 proteins enhance the activity of H9 exosomesagainst L1 retrotransposition. One such candidate could be A3C which
modestly inhibits L1 (Bogerd et al., 2006b; Kinomoto et al., 2007;
Muckenfuss et al., 2006). The possibility that exosomal mRNAs are
translated in recipient cells after exosome internalization has been
well documented (Deregibus et al., 2007; Ratajczak et al., 2006a; Skog
et al., 2008; Valadi et al., 2007). We have found that H9 exosomes
encapsidate mRNAs coding for A3C, A3F and A3G. Further analysis
showed that A3G mRNA isolated from exosomes is functional and
supports protein synthesis in an in vitro translation system. Based on
these observations, we speculate that transfer of functional A3
proteins and corresponding mRNAs modulate or enable cells to resist
invading or endogenous retroelements.
Alu retrotransposition was profoundly inhibited by H9 exosomes
and moderately inhibited by M-DC exosomes. Since H9 exosomes
encapsidated not only A3G but also A3F, we investigated whether A3G
in exosomes inhibits Alu mobilization. A short interfering RNA
(siRNA) approach to downregulate A3G in H9 cells was unsuccessful.
However, introduction of A3G gene into A3G-negative CD4+SupT1
cells that expressed low levels of A3F showed that exosomes secreted
by the cells reduced Alu retrotransposition by 68%. This result
conﬁrms that exosomal A3G inhibits Alu but does not rule out the
possibly that additional factors (e.g. A3F), likely in combination with
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A3G and one preparation (donor 2) contained small amounts of A3F.
However, all tested blood-derived microvesicles (3 different donors)
did not show any effect on L1 or Alu retrotransposition.
The mechanism of exosome entry and delivery of its cargo into the
cell cytoplasm without degradation in the lysosomal compartment is
unknown. However, the observation that some cellular receptors
(Mack et al., 2000), transcription factors (Ratajczak et al., 2006a) or
mRNAs (Deregibus et al., 2007; Ratajczak et al., 2006a; Valadi et al.,
2007) transferred by microvesicles or exosomes remain functional in
recipient cells, supports the notion that molecules delivered by
exosomes escape degradation.
Another unanswered question is how A3 proteins are packaged
into exosomes. One possibility is that cytoplasmic molecules may be
engulfed during the inward budding of limiting membranes of MVBs.
However, this non-speciﬁc mechanism does not explain speciﬁc
enrichment of some molecules (e.g. A3F or A3G mRNA) in exosomes.
The ability of A3 proteins to interact with certain mRNAs and small
noncoding RNAs (Chiu et al., 2006; Gallois-Montbrun et al., 2008;
Khan et al., 2007; Kozak et al., 2006; Wang et al., 2007b, 2008b)
suggests that A3 proteins may localize into exosomes indirectly by
interaction with cellular RNAs. Although packaging of A3G into HIV-1
particles is mediated by HIV-1 Gag and cellular RNAs (Alce and Popik,
2004; Cen et al., 2004; Douaisi et al., 2004; Luo et al., 2004; Navarro et
al., 2005; Schafer et al., 2004; Svarovskaia et al., 2004; Zennou et al.,
2004), packaging into exosomes obviously does not require HIV-1
Gag. Our ﬁndings that exosomes encapsidate large quantities of 7SL
RNA (not shown) together with previous observations that A3G
interacts with 7SL RNA (Bach et al., 2008; Wang et al., 2007b, 2008c),
suggests that 7SL RNAmaymediate A3G encapsidation into exosomes
in a Gag-independent manner. Since A3G is able to interact with
diverse retrotransposon Gag proteins (Bogerd et al., 2006a; Dutko et
al., 2005), we cannot dismiss the possibility that A3G interacts with
endogenous retroviral Gag and cellular RNA (including 7SL RNA)
complexes to gain access to exosomes. The mechanism by which
other A3 proteins gain access into exosomes is presently unknown.
The biological signiﬁcance of exosomes bearing encapsidated A3
proteins and respective mRNAs is unknown. One possibility is that
encapsidation of A3 in exosomes may serve to dispose of excess
cytidine deaminases that might otherwise lead to genomic instability
(Anant and Davidson, 2003; Pham et al., 2005). However, we
speculate that exosomes with encapsidated A3 proteins may serve
to ﬁne tune the response against transiently expressed retroelements
in germ cells or during the early stages of human embryogenesis
(Garcia-Perez et al., 2007; Kazazian, 2004; Sawyer et al., 2004). In
addition, exosomes with encapsidated A3 proteins may control
retrotransposition which may occasionally occur in somatic cells
(Kubo et al., 2006; Schulz, 2006).
In conclusion, the ﬁndings reported here show for the ﬁrst time
that exosomes packaging A3G and A3F potently restrict mobilization
of L1 and Alu in recipient cells in vitro. Whether exosomes contribute
to restriction of mobilization of retroelements in vivo will require
further investigation.
Materials and methods
Cells
SupT1, H9 and peripheral blood mononuclear cells (PBMCs) were
propagated in RPMI supplemented with 10% FCS and gentamicin
(50 μg/ml; complete RPMI). HeLa and 293T cells were cultivated in
DMEM supplemented with 10% FCS and gentamicin (complete
DMEM). PBMCs were obtained by Ficoll-Paque (Amersham) density
centrifugation from healthy blood donors (New York Blood Center).
Monocyte-derived dendritic cells (M-DC) were obtained from the
plastic adherent fraction of PBMC. After 3 h adherence to plasticdishes, adherent cells were washed, collected by scraping and plated
in T75 ﬂask at 2×106 cells/ml. The cells were cultivated for 6 days
with 5 ng/ml interleukin-4 (IL-4; Humzyme) and 5 ng/ml granulo-
cyte-macrophage colony-stimulating factor (GM-CSF; Humzyme) in
complete RPMI. Maturation of M-DCwas induced by incubation of the
immature M-DC with 10 ng/ml of lipopolysaccharide (LPS; Escheri-
chia coli strain O55:B5, Sigma-Aldrich) as described (Wang et al.,
2007a). The M-DCs were more than 94% pure by HLA-DR and CD11c
staining (FACS analysis).
Plasmids
Human A3-HA expression vectors were obtained from B. R. Cullen
and A3H-V5 from Y. Zheng. L1RP-EGFP and EFO5J were obtained from
E. T. L. Prak and H. H. Kazazian. Alu neoTet and p220.CMV L1-RP was
provided by T. Heidmann.
L1 retrotransposition assay
293T cells were plated one day before transfection in 12-well
plates at 2×105 cells/well in complete DMEM. The cells were
transfected using the PolyFect reagent (Qiagen) and 1 μg of the L1
retrotransposition reporter plasmid without or with 0.5 μg of A3-HA
or A3H-V5-His (Dang et al., 2008). The total amount of transfected
DNA was adjusted to 1.5 μg with control pcDNA3.1 vector. After 3 h,
the transfection medium was replaced with complete DMEM for
another 3 h. Exosomes (20 μg) were added where indicated and
incubated with cells for 24 h. The following day, new aliquots of
exosomes were added and incubated with cells for another 24 h.
Three days post-transfection, the cells were trypsinized and trans-
ferred to 60-mm dishes. On days 5–7 post-transfection, the cells were
analyzed for GFP expression by ﬂuorescent microscopy and ﬂow
cytometry (FACSCalibur, BD). FACS analysis was performed on ﬁxed
cells and retrotransposition frequency was determined by gating GFP-
positive cells.
L1-mediated Alu retrotransposition assay
HeLa cells (1.1×105 cells/well) were cotransfected using PolyFect
(Qiagen) in 12-well plates with 1 μg of neoTet-marked Alu and 0.5 μg
pCMV-L1 (p220 L1-RP). In control experiments, the cells were
additionally cotransfected with A3G-V5 or GFP vectors. Negative
controls were mock transfected or transfected with Alu, L1, or Alu and
GFP. The transfected cells were incubated with different exosome
preparations (20 μg), starting 6 h post-transfection with an additional
dose of exosomes added next day. Three days post-transfection, the
cells were trypsinized and transferred to 60-mm dishes. Starting at
day 7 post-transfection, the cells were selected in the presence of
G418 (1 mg/ml; Invitrogen) and the media were changed daily. One
week later, the G418-resistant cell foci were ﬁxed with 3%
paraformaldehyde, stained with 1% crystal violet, washed, air-dried
and counted using Quantity One software (ChemiDoc XRS, Bio-Rad).
Quantitative real-time RT-PCR analysis
Total RNA was extracted and puriﬁed using a total RNA
puriﬁcation kit (Norgen) and contaminating DNA was digested with
Turbo DNA-free DNase (Ambion). Puriﬁed RNA (200 ng) was reverse
transcribed to cDNA using an iScript cDNA synthesis kit (Bio-Rad) and
subjected to real-time PCR using primers speciﬁc for human A3 genes
(SABiosciences). Ampliﬁcation of A3 genes was normalized to GAPDH
as an endogenous control. Normalized expression of A3C in H9 cells or
H9 exosomes was set as 1.0. The experiment was repeated twice with
triplicate cDNA samples used for PCR.
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Exosome preparation was performed as previously described
(Khatua et al., 2009). In short, cells were grown in culture media
supplemented with 10% FCS depleted of endogenous exosomes.
Culture supernatants were collected every 24 h and were ﬁrst
centrifuged at 300×g for 10 min to pellet cells. Cell debris was
removed from the resulting supernatant by centrifugation at 2000×g
for 15 min followed by 30 min centrifugation at 10,000×g. The
clariﬁed supernatant was ﬁltered through a 0.45 μm ﬁlter and
ultracentrifuged at 100,000×g using a SW32 rotor to pellet exosomes.
Exosomes were washed by resuspension in PBS and pelleted for 1 h at
100,000×g using a SW41 rotor. After suspension in a small volume
(50–100 μl) of PBS, puriﬁed exosomes were aliquoted and stored at
−80 °C. Protein concentration of exosome preparations was deter-
mined using Micro BCA protein assay (Thermo Scientiﬁc).
PolyA+mRNA isolation and in vitro translation
PolyA+mRNA was isolated directly from H9 exosomes using
Oligotex direct mRNA protocol according to the manufacturer's
speciﬁcations (Qiagen). One μg of polyA+mRNA was used for in
vitro translation using human in vitro protein expression kit according
to manufacturer's recommendation (Thermo Scientiﬁc). A sample
without added RNA was used as a negative control. GFP mRNA was
used as a positive control. Translation reactions (25 μl) were
performed for 90 min at 30 °C and total reaction volumes were
subjected to Western blot analysis.
Western blot analysis
Proteins were separated on SDS-10% polyacrylamide gels and
analyzed as described (Khatua et al., 2009). Antibodies for Western
blotting were obtained from the following sources; rabbit anti-Alix
from H. Stenmark (Oslo, Norway), rabbit anti-A3G from K. Strebel
(NIH), rabbit anti-GFP, monoclonal anti-HA and anti-V5 antibodies
from Invitrogen, rabbit anti-Rab7 from Santa Cruz Biotechnology.
Rabbit anti-A3F antibodies were obtained through the NIH AIDS
Research and Reference Reagent Program, Division of AIDS, NIAID,
NIH.
Statistical analysis
All experiments were repeated at least three times with similar
results. The variations in single experiments were expressed by
calculating the standard deviation (SD) from triplicate samples and
presented as the mean values±SD.
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